Boston University researchers to develop new breast tumor models
Breast cancer is the second most common cancer diagnosed in women in the United States after skin cancer, and women with comorbidities (the presence of more than one condition/disease) often fare worse in terms of their breast cancer. Researchers believe that comorbid conditions such as diabetes, obesity and metabolic disease may alter the biology of the non-malignant cells of the tumor microenvironment and may promote progression.
Boston University School of Medicine (BUSM) researchers Gerald Denis, PhD, Andrew Emili, PhD, and Stefano Monti, PhD, together with Beth Israel Deaconess/Harvard Medical School researcher Senthil Muthuswamy, PhD, have been awarded a five-year, $2.5 million National Cancer Institute UO1 grant to develop and analyze breast tumor organoids (models). Specifically, the award will support their project: Multiscale analysis of metabolic inflammation as a driver of breast cancer.